News

Article

OKYO Pharma files IND with US FDA for the development of OK-101 to treat Neuropathic Corneal Pain (NCP)

According to the company, study enrollment is planned to commence during Q1 2024 following IND allowance by the FDA.

(Image credit: AdobeStock/monticellllo)

(Image credit: AdobeStock/monticellllo)

OKYO Pharma has announced it has filed an Investigation New Drug (IND) application with the US Food and Drug Administration (FDA) for the development of OK-101 to treat Neuropathic Corneal Pain (NCP). According to the company, study enrollment is planned to commence during Q1 2024 following IND allowance by the FDA.1

With no FDA-approved drug to treat NCP, OKYO stated in a press release that this remains a major unmet medical need for the ocular community.1

“The open-label trial will provide an opportunity to evaluate the safety and efficacy of OK-101 for NCP in a real-world clinical setting, fostering a better understanding of its potential benefits for patients,” said the company in the release.

Pedram Hamrah, MD, Professor and Vice Chair of Research and Academic Programs, Co-Director of the Cornea Service and Director of the Center for Translational Ocular Immunology at Tufts Medical Center, will lead the NCP trial according to OKYO. Hamrah, a leading expert in NCP and co-inventor on the OK-101 patent, is a member of OKYO’s scientific advisory board and plants to serve as principal investigator of the study that will be held at Tufts Medical Center.1

“NCP, which can exhibit as a severe, chronic or debilitating condition in patients suffering from a host of ophthalmic conditions, is presently treated by various topical and systemic treatments in an off-label fashion,” said Hamrah in the release. “However, there are no approved commercial treatments currently available for this condition, and consequently we are looking forward to initiating the clinical trial to investigate the potential efficacy of OK-101 to treat symptoms of NCP.”

“We are excited about OK-101’s dual combination of anti-inflammatory ocular activity and NCP reducing activity and are eager to evaluate this drug to treat NCP while awaiting the top-line data for OK-101 from the ongoing Phase 2 DED trial which is planned for released in December 2023,” said Gary S Jacob, PhD, CEO of OKYO.

OK-101 is also being tested for the treatment of dry eye disease, and is currently in a Phase 2, multicenter, double-masked, placebo-controlled trial.

References:
  1. OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (“NCP”). Press Release. Released October 9, 2023. Accessed October 9, 2023. https://okyopharma.com/okyo-pharma-announces-filing-of-an-investigational-new-drug-ind-application-for-ok-101-to-treat-neuropathic-corneal-pain-ncp/

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
Brett Bielory, MD, discusses his poster at the ASCRS annual meeting, which focuses on an under-diagnosed corneal pathology: neurotrophic keratitis.
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
(Image credit: Ophthalmology Times) World Cornea Congress IX: Epi-on and accelerated crosslinking with Kenneth Beckman, MD
(Image credit: Ophthalmology Times) The synergy of cornea, cataract, and refractive surgery through the decades: insights from George O. Waring IV, MD
Lana Rifkin, MD, uveitis committee chair at EnVision Summit 2025
© 2025 MJH Life Sciences

All rights reserved.